Connect with us

European Alliance for Personalised Medicine

Announcement: Framing the discussion with stakeholders for Access, competitive and innovation in the context of the Access to healthcare – Virtual Event, 7 March, 2023

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

On Tuesday, 7 March, a virtual conference/webinar will take place under banner title which is ‘Framing the discussion with stakeholders for Access, competitive and innovation in the context of the Access to healthcare as well as EU Industrial policy.  

We would like to take this opportunity to invite you to join us for this series of expert panels which runs over from 09.30 CET until 16.10 CET.

To view the agenda, please click HERE and to register, please click HERE.

Given the current global attention to the demands of an adequate healthcare system and the heightened interest in public health in general, this online series of expert panels will address what can be done to ensure that the health systems of the future are resilient enough to not only handle shocks like a global pandemic but also respond those underlying forces that are shaping future healthcare needs. 

Participants will hear from a variety of Expert Panel members exploring how governments can allocate resources between competing public health demands, and how available technologies can help.

Background:  The chance exists to re-align priorities to evaluate the needs of patients, healthcare professionals and health systems to facilitate improved and safer therapies.

There is also space and necessity for enhanced collaboration between EU regulatory and payer groups. This would have the aim of identifying core outcomes other than survival that can be incorporated into trials, as well as healthcare systems, to generate data throughout the lifecycle.

Among others, the conference will pose the following questions:

Advertisement
  •  How does Europe reconcile rapid access to innovation while incentivising necessary continued research to demonstrate value and societal benefits of new medical products, including IVDs?
  • What are the unmet health needs to support the patients and the healthcare professional
  • What are the differences that affect regulatory vs payer decisions?
  •  What specific data elements would allow for efficient assessment of products providing significant benefit to patients?
  • Can we find an agreed European (and possibly global) approach to quantifying clinical benefit?
  •  Are there clinical outcomes other than survival that can be agreed upon to be used in registration trials and healthcare systems?
  • How do we best explain the need for both clinical research and ongoing data collection to patients and society and its benefit to both?

The sessions for the series of expert panels include the following:

  • Consensus Panel I: Familiar challenges and new complications
  • Consensus Panel II: Shortage of healthcare professionals: Training and the need for investment
  • Consensus Panel III: Keeping the Person in Personalised Healthcare
  • Consensus Panel IV: Policy Framework  

Once again, to view the agenda, please click HERE and to register, please click HERE.  Please see attached the agenda also.

We’d love you to join us on 7 March. 

Share this article:

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter.

Trending